VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER)

Descriptive : A 12-months multicenter, observational, prospective cohort study. Population : IBD patients under stable clinical and biological remission will be proposed to switch from the IV vedolizumab to the SC vedolizumab as part of routine care. All consecutive IBD patients in IBD centers participating in the study will be proposed to participate in the study during their regular outpatients' visits. Objectives : The primary objective of DOPER study is to describe SC vedolizumab persistence after switching from IV vedolizumab to SC vedolizumab at month 12.

NCT Number	NCT05158517
Lead Sponsor	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives Collaborators: Takeda
Conditions	Inflammatory Bowel Diseases
Enrollment	349 participants
Start Date	2022-03-20
Primary Completion	2024-03-31 (estimated)
Study Completion	2025-03-20 (estimated)
Updated on ClinicalTrials.gov	2024-07-22